1,602 results on '"Gallamini, A."'
Search Results
52. Standardization of 18F-FDG–PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma
53. PET-guided clinical trials in Hodgkin lymphoma: to agree or not to agree, that is the reviewer’s question
54. The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium
55. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study
56. High-risk relapsed or refractory classic Hodgkin lymphoma cure: how to make the impossible possible
57. SIE-SIES-GITMO Guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias
58. Design of a Programmable Bioelectrical Impedance System for Biomedical Applications.
59. Functional Imaging
60. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma
61. Peripheral Blood CD34+ Percentage at Hematological Recovery after Chemotherapy Is a Good Early Predictor of Harvest: A Single-Center Experience
62. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)
63. Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy
64. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkinʼs Lymphoma
65. Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study
66. The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin’s lymphoma patients—the Polish Lymphoma Research Group (PLRG) Observational Study
67. The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium.
68. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program
69. FDG-PET SCAN: A NEW PARADIGM FOR FOLLICULAR LYMPHOMA MANAGEMENT.
70. AN EXAMPLE OF PROSPECTIVE APPLICATION OF IMAGING BIOMARKER: SET-UP OF THE FIRST WORLDWIDE PROSPECTIVE PHASE III ONCO-HEMATOLOGICAL CLINICAL TRIAL USING TMTV FOR PATIENT STRATIFICATION
71. Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe)
72. Positron Emission Tomography (PET) in Oncology
73. Ultra-Low-Level Laser Stimulation of LU7 Lieque Promotes Breath Functionality: Could it be of help in Covid 19 Rehabilitation? - A Multiple Case Report
74. Transdermal Delivery of Active Principles with Pulsed RF Contact Diathermy - A Narrative Review
75. Ultra-Low-Level Laser Therapy and Acupuncture Libralux: What Is so Special?
76. First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1.
77. S200: IMPROVED OVERALL SURVIVAL WITH FIRST-LINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IN PATIENTS WITH STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: 6-YEAR ANALYSIS OF ECHELON-1
78. Assessment of Body Composition and Physical Performance of Young Soccer Players: Differences According to the Competitive Level
79. Concomitant semi-quantitative and visual analysis improves the predictive value on treatment outcome of interim 18F-fluorodeoxyglucose/positron-emission tomography in advanced Hodgkin lymphoma
80. Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial
81. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study
82. Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials?
83. Multicenter Experience Using Total Lymphoid Irradiation and Antithymocyte Globulin as Conditioning for Allografting in Hematological Malignancies
84. PET response-adapted clinical trials in Hodgkin lymphoma: a comprehensive review
85. Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease
86. FDG PET/CT imaging as a biomarker in lymphoma
87. Concomitant semi-quantitative and visual analysis improves the predictive value on treatment outcome of interim 18F-fluorodeoxyglucose/positron-emission tomography in advanced Hodgkin lymphoma
88. Modulation of Gluteus Medius Strength by Yang Qiao Mai Stimulation: A Multiple Case Report
89. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma
90. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial
91. Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?
92. Hodgkin Lymphoma: Recent Progress in Overall Management
93. HL-507 First-Line Brentuximab Vedotin Plus Chemotherapy Improves Overall Survival in Patients With Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1
94. Cortical alpha rhythms are correlated with body sway during quiet open-eyes standing in athletes: A high-resolution EEG study.
95. Chemoresistance As a Function of the Pretherapy Tumor Burden and the Chemotherapy Regimen Administered: Differences Observed With 2 Current Chemotherapy Regimens for Advanced Hodgkin Lymphoma
96. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma
97. Fused FDG–PET/contrast-enhanced CT detects occult subdiaphragmatic involvement of Hodgkin's lymphoma thereby identifying patients requiring six cycles of anthracycline-containing chemotherapy and consolidation radiation of spleen
98. A Score-Based Approach to 18F-FDG PET Images as a Tool to Describe Metabolic Predictors of Myocardial Doxorubicin Susceptibility
99. Lesion Dissemination in Baseline PET/CT (D-MAX) and IPS Score Predict ABVD Treatment Outcome in PET-2 Negative Advanced-Stage Hodgkin Lymphoma Patients Enrolled in the Prospective GITIL/FIL HD0607 Trial
100. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.